Therapeutic targeting of miR-128-1 in Duchenne muscular dystrophy

杜氏肌营养不良症中 miR-128-1 的治疗靶点

基本信息

批准号：
10626685
负责人：
Sona Kang
金额：
$ 40.13万
依托单位：
UNIVERSITY OF CALIFORNIA BERKELEY
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-08-01 至 2024-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10626685
关键词：
Animal Model Antisense Oligonucleotides Area Autophagocytosis Bioenergetics Biogenesis Biology Birth Blood Circulation CRISPR correction Cardiac Cells Cessation of life Characteristics Childhood Data Defect Dependovirus Disease Disease Progression Duchenne muscular dystrophy Dystrophin Functional disorder Genes Goals Hand Strength Health Homeostasis Human In Vitro Incidence Individual Inherited Investigation Knock-out Knockout Mice Life Link Lung Mediating Metabolism MicroRNAs Mitochondria Modeling Molecular Monitor Motor Mouse Strains Mus Muscle Muscle Cells Muscle Fibers Muscle function Muscular Atrophy Muscular Dystrophies Mutation Myocardium Natural regeneration Neuromuscular Diseases Pathology Patients Peroxisome Proliferator-Activated Receptors Pharmacology Phenotype Play Process Publishing RNA Reagent Reporter Role SIRT1 gene Signaling Protein Skeletal Muscle Steroids Symptoms Testing Therapeutic Therapeutic Effect Therapeutic Intervention Treatment Efficacy Treatment Protocols Wasting Syndrome Zebrafish antisense nucleic acid biobank canine model effective therapy exercise intolerance exon skipping therapy genetic regulatory protein genomic locus improved in vivo jagged1 protein locked nucleic acid male mitochondrial autophagy mitochondrial metabolism motor disorder mouse model muscle degeneration muscle metabolism muscular dystrophy mouse model notch protein novel therapeutic intervention novel therapeutics overexpression respiratory skeletal skeletal muscle metabolism skeletal muscle wasting subcutaneous symptomatic improvement therapeutic target transcriptomics

项目摘要

Project Summary/Abstract Duchenne muscular dystrophy (DMD), an X-linked inherited neuromuscular disorder, has a worldwide incidence of one in ~3,500-5,000 live male births, making it the most common muscular dystrophy. DMD is caused by mutations in the dystrophin gene, resulting in a progressive muscle-wasting disorder due to loss of skeletal and cardiac muscle. It is an early lethal disease, and most afflicted males die in their 20’s or 30’s of cardiac or respiratory complications. There is thus an urgent need for novel therapeutic avenues for the treatment of DMD as the current treatments have only limited efficacy. The molecular mechanisms mediating deleterious effects downstream of dystrophin loss remain unclear. We note that the expression of the miR-128-1 microRNA is elevated in the muscle and circulation of human DMD patients, and in muscle of mouse and zebrafish DMD models. Moreover, the miR-128-1 genomic locus is markedly linked to weak grip strength and poor lung muscle function in the UK Biobank (>300,000 individuals). Our preliminary studies from the zebrafish and mouse models of DMD have found that inhibition of miR-128-1 using locked nucleic acid (LNA) antisense oligos (ASO) dramatically mitigates the DMD phenotypes, including muscle atrophy and exercise intolerance. Furthermore, our preliminary studies have revealed that miR-128-1 inhibition largely rescues the expression of a suite of key genes involved in skeletal mitochondrial health and energy homeostasis, accompanied by improved mitochondrial biogenesis and function in vitro and in vivo. In this application, we propose studies to test the hypothesis that miR-128-1 represents a crucial disease modifier that orchestrates the deleterious effects of dystrophin loss by regulating a set of key target genes that are important for mitochondrial health and putative target genes that are critical for muscle metabolism. In the first Aim, we will investigate what roles miR-128-1 play in mediating mitochondrial abnormalities in DMD and assess whether improving mitochondrial function by combining miR-128-1 inhibition and pharmacological activators of mitochondrial function can synergistically ameliorate muscle dysfunction in the mdx5cv mouse DMD model and in human DMD patient-derived muscle cells. In addition, we will comprehensively identify miR-128-1 target genes in mdx5cv mice by performing transcriptomic analysis and assess human conservation. In the second Aim, we will evaluate the therapeutic efficacy of miR-128-1 inhibition in the mouse mdx5cv DMD model using LNA ASOs, as well as conditional mouse KO of miR-128-1 and muscle-targeted adeno-associated virus approaches. Successful completion of the proposed studies will determine whether miR-128-1 may indeed represent a powerful therapeutic target in DMD, and reveal the downstream mechanism whereby miR-128-1 mediates the DMD pathologies.

项目概要/摘要杜氏肌营养不良症 (DMD) 是一种 X 连锁遗传性神经肌肉疾病，具有全球范围内，每 3,500-5,000 名活产男婴中就有 1 人发病，使其成为最常见的疾病肌营养不良症是由肌营养不良蛋白基因突变引起的。由于骨骼肌和心肌丧失而导致的进行性肌肉萎缩症，这是一种早期疾病。致命疾病，大多数受影响的男性在 20 多岁或 30 多岁时死于心脏病或呼吸系统疾病因此，迫切需要新的治疗途径来治疗并发症。 DMD 作为目前的治疗方法，其调节的分子机制效果有限。我们注意到抗肌营养不良蛋白损失的下游有害影响仍不清楚。人类 DMD 患者的肌肉和循环中 miR-128-1 microRNA 的含量升高，此外，在小鼠和斑马鱼 DMD 模型的肌肉中，miR-128-1 基因组位点是英国生物银行认为，与握力较弱和肺肌肉功能较差有显着相关（超过 300,000 人）。我们对 DMD 斑马鱼和小鼠模型进行的初步研究。发现使用锁核酸 (LNA) 反义寡核苷酸 (ASO) 抑制 miR-128-1 显着减轻 DMD 表型，包括肌肉萎缩和运动不耐受。此外，我们的初步研究表明，miR-128-1 抑制在很大程度上挽救了涉及骨骼线粒体健康和能量的一系列关键基因的表达体内平衡，伴随着体外和体内线粒体生物合成和功能的改善在本申请中，我们提出研究来检验 miR-128-1 代表的假设。关键的疾病调节剂，通过调节肌营养不良蛋白损失来协调有害影响一组对线粒体健康很重要的关键靶基因和假定的靶基因在第一个目标中，我们将研究 miR-128-1 的作用。在介导 DMD 线粒体异常中发挥作用并评估是否改善通过结合 miR-128-1 抑制和药物激活剂来调节线粒体功能线粒体功能可以协同改善 mdx5cv 小鼠的肌肉功能障碍此外，我们还将研究 DMD 模型和人类 DMD 患者来源的肌肉细胞。通过转录组学全面鉴定 mdx5cv 小鼠中的 miR-128-1 靶基因分析和评估人类保护。在第二个目标中，我们将评估治疗方法。使用 LNA ASO 在小鼠 mdx5cv DMD 模型中抑制 miR-128-1 的功效，以及条件性小鼠 miR-128-1 敲除和肌肉靶向腺相关病毒方法。成功完成拟议的研究将确定 miR-128-1 是否确实可以代表 DMD 的强大治疗靶点，并揭示下游机制因此 miR-128-1 介导 DMD 病理。